Exploring biomarkers in pulmonary fibrosis and sarcoidosis
Host-microbiome Interactions in the Quest for Fibrosing ILD Biomarkers That Rule Acceleration
This study is trying to find new biological markers in patients with pulmonary fibrosis and sarcoidosis to see how these markers can help understand the disease better and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Universidade do Porto Academic / other |
| Locations | 1 site (Porto) |
| Trial ID | NCT05635032 on ClinicalTrials.gov |
What this trial studies
FIBRALUNG is a prospective cohort study that collects biological samples from patients with pulmonary fibrosis and related conditions to investigate the molecular factors influencing clinical outcomes, acute exacerbations, and mortality. The study aims to identify common pathways in fibroproliferative diseases, particularly between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. By analyzing these samples, researchers hope to discover new biomarkers that indicate disease progression and could lead to targeted therapies. Additional patients with other interstitial lung diseases and sarcoidosis will also be included for further analysis.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18-80 with a recent HRCT scan showing significant lung fibrosis and who are treatment-naïve.
Not a fit: Patients who cannot provide informed consent or are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of new biomarkers and targeted therapies for patients with pulmonary fibrosis and sarcoidosis.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for pulmonary diseases, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged between 18-80 years * People undergoing blood collection, lung biopsy and/or BAL as part of their diagnostic workup * Willingness to undergo the follow-up protocol evaluations * Treatment-naïve for disease-modifying drugs * An HRCT scan performed within the last 12 months showing ≥10% fibrosis extent of the lungs Exclusion Criteria: * People who cannot give informed consent * Pregnancy
Where this trial is running
Porto
- Centro Hospitalar Universitário São João — Porto, Portugal (Recruiting)
Study contacts
- Principal investigator: Helder Novais Bastos, MD, PhD — Universidade do Porto
- Study coordinator: Helder Novais Bastos, MD, PhD
- Email: hnovaisbastos@med.up.pt
- Phone: (+351) 220408800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.